Literature DB >> 19519229

The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients.

Allison J Applebaum1, Laura C Reilly, Jeffrey S Gonzalez, Mark A Richardson, Catherine L Leveroni, Steven A Safren.   

Abstract

This study assessed the frequency of neuropsychological impairment and its relationship to adherence in a sample of HIV-infected injection drug users (IDUs) in treatment. One hundred eight participants recruited between September 2006 and October 2008 completed psychodiagnostic and neuropsychological assessments and monitored HAART adherence over a 2-week period via the use of Medication Event Monitoring System (MEMS) electronic pill caps and self-report. Assessment of concurrent functioning included clinician-rated scales of depression and substance use severity, and a battery of neuropsychological tests. Findings from individual neuropsychological tests were converted to Z scores relative to standard norms and averaged to form a composite score (NPZ). NPZ was generally poor (mean = -1.505, standard deviation = 1.120), with 76.9% of the sample being classified as highly impaired. Self-reported adherence was significantly higher than MEMS cap adherence. In contrast with previous studies, overall neuropsychological functioning was not a significant predictor of electronically monitored or self-reported adherence. However, examiner-rated current global severity of substance use and delayed word list recall emerged as significant predictors of self-reported adherence. Additionally, estimated premorbid verbal intelligence emerged as a significant predictor of the discrepancy between electronically monitored and self-reported adherence. Given the extent of neuropsychological impairment in this sample, future studies should examine the degree to which the impact of neuropsychological impairment may moderate interventions for this population, and the extent to which skills to cope with neuropsychological problems may boost the potential efficacy of such interventions.

Entities:  

Mesh:

Year:  2009        PMID: 19519229      PMCID: PMC2856567          DOI: 10.1089/apc.2008.0181

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  59 in total

1.  Response to systemic HIV viral load suppression correlates with psychomotor speed performance.

Authors:  N Sacktor; R L Skolasky; P M Tarwater; J C McArthur; O A Selnes; J Becker; B Cohen; B Visscher; E N Miller
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

2.  Initial validation of a screening battery for the detection of HIV-associated cognitive impairment.

Authors:  Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; David J Moore; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  Clin Neuropsychol       Date:  2004-05       Impact factor: 3.535

3.  Adherence to antiretroviral medications in HIV: differences in data collected via self-report and electronic monitoring.

Authors:  Andrew J Levine; Charles H Hinkin; Sarah Marion; Allison Keuning; Steven A Castellon; Mona M Lam; Marta Robinet; Douglas Longshore; Thomas Newton; Hector Myers; Ramani S Durvasula
Journal:  Health Psychol       Date:  2006-05       Impact factor: 4.267

4.  Effectiveness of psychosocial interventions in preventing HIV risk behaviour in injecting drug users.

Authors:  D R Gibson; J McCusker; M Chesney
Journal:  AIDS       Date:  1998-05-28       Impact factor: 4.177

5.  Problem drinking and medication adherence among persons with HIV infection.

Authors:  R L Cook; S M Sereika; S C Hunt; W C Woodward; J A Erlen; J Conigliaro
Journal:  J Gen Intern Med       Date:  2001-02       Impact factor: 5.128

6.  Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment.

Authors:  V Di Sclafani; R D Mackay; D J Meyerhoff; D Norman; M W Weiner; G Fein
Journal:  J Int Neuropsychol Soc       Date:  1997-05       Impact factor: 2.892

7.  Cognitive impairment among methadone maintenance patients.

Authors:  S Darke; J Sims; S McDonald; W Wickes
Journal:  Addiction       Date:  2000-05       Impact factor: 6.526

8.  [Adherence to antiretroviral therapy measured by pill count and drug serum concentrations. Variables associated with a bad adherence].

Authors:  Melcior Riera; Laura de La Fuente Ld; Bartomeu Castanyer; Francesc Puigventós; Concepción Villalonga; M Angels Ribas; Antonio Pareja; Maria Leyes; Ana Salas
Journal:  Med Clin (Barc)       Date:  2002-09-14       Impact factor: 1.725

9.  A comparison of the trail making test, symbol digit modalities test, and the Hooper Visual Organization Test in an inpatient substance abuse population.

Authors:  R J McCaffrey; M M Krahula; R G Heimberg; K E Keller; M J Purcell
Journal:  Arch Clin Neuropsychol       Date:  1988       Impact factor: 2.813

10.  Neurocognitive function in HIV-infected patients with low weight and weight loss.

Authors:  Sara Dolan; Andrea Montagno; Stephanie Wilkie; Negar Aliabadi; Meghan Sullivan; Nicole Zahka; Janet Cohen Sherman; Steven Grinspoon
Journal:  J Acquir Immune Defic Syndr       Date:  2003-10-01       Impact factor: 3.731

View more
  22 in total

1.  HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence.

Authors:  David J Moore; Carolina Posada; Mili Parikh; Miguel Arce; Florin Vaida; Patricia K Riggs; Ben Gouaux; Ronald J Ellis; Scott L Letendre; Igor Grant; J Hampton Atkinson
Journal:  AIDS Behav       Date:  2012-11

Review 2.  Implementation challenges for long-acting antivirals as treatment.

Authors:  Diane Havlir; Monica Gandhi
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

Review 3.  Neurocognitive impact of antiretroviral treatment: thinking long-term.

Authors:  Megan E McPhail; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

4.  Depression longitudinally mediates the association of appearance concerns to ART non-adherence in HIV-infected individuals with a history of injection drug use.

Authors:  Aaron J Blashill; Janna R Gordon; Steven A Safren
Journal:  J Behav Med       Date:  2012-11-22

Review 5.  Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis.

Authors:  Olalekan A Uthman; Jessica F Magidson; Steven A Safren; Jean B Nachega
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 6.  A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence.

Authors:  Mohamed El Alili; Bernard Vrijens; Jenny Demonceau; Silvia M Evers; Mickael Hiligsmann
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

Review 7.  Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review.

Authors:  Alisha Monnette; Yichen Zhang; Hui Shao; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

8.  The relationship between cognitive change and physical health and behavioural outcomes in a Ugandan cohort of adults living with HIV - a longitudinal study.

Authors:  G Spies; C A Denckla; S Mall; J Levin; S Seedat; N Nakasujja; E Kinyanda
Journal:  AIDS Care       Date:  2018-11-13

9.  Psychosocial Syndemics are Additively Associated with Worse ART Adherence in HIV-Infected Individuals.

Authors:  Aaron J Blashill; C Andres Bedoya; Kenneth H Mayer; Conall O'Cleirigh; Megan M Pinkston; Jocelyn E Remmert; Matthew J Mimiaga; Steven A Safren
Journal:  AIDS Behav       Date:  2015-06

Review 10.  An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research.

Authors:  Lisa R Norman; Michael Basso
Journal:  Curr Drug Abuse Rev       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.